Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Checks And Balances For Orphan Drugs Needed, Says Germany’s G-BA

Executive Summary

The German pricing and reimbursement authority wants better scrutiny of orphan drug designations and incentives for orphan drug development to help address the access problem.

Advertisement

Related Content

Interview: Eucope On Turning Ten, Defending Orphan Incentives And Securing Market Access For Cell And Gene Therapies
EU Orphan Designations Fall Sharply In 2017
Lessons From Europe: Orphan Drug Valuations Show Limits Of Cost Effectiveness
Scrip Asks… What Will Happen In Orphan Drug Pricing In The Next Five Years?
New Guidance Brings Welcome Clarity on Practical Application of EU Orphan Drugs Law

Topics

Advertisement
UsernamePublicRestriction

Register

PS120110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel